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Can Vitamin C Prevent Complex Regional 
Pain Syndrome in Patients with Wrist Fractures?
A Randomized, Controlled, Multicenter Dose-Response Study
By P.E. Zollinger, MD, W.E. Tuinebreijer, MD, PhD, MSc, MA, R.S. Breederveld, MD, PhD, and R.W. Kreis, MD, PhD
Investigation performed at the Department of Surgery, Red Cross Hospital, Beverwijk, The Netherlands; 
the Department of Orthopaedics and Surgery, Haga Hospital (Leyenburg), The Hague, 
The Netherlands; and the Department of Orthopaedics and Surgery, Reinier de Graaf Group, Delft, The Netherlands
Background: Complex regional pain syndrome type I is treated symptomatically. A protective effect of vitamin C
(ascorbic acid) has been reported previously. A dose-response study was designed to evaluate its effect in patients
with wrist fractures.
Methods: In a double-blind, prospective, multicenter trial, 416 patients with 427 wrist fractures were randomly allo-
cated to treatment with placebo or treatment with 200, 500, or 1500 mg of vitamin C daily for fifty days. The effect of
gender, age, fracture type, and cast-related complaints on the occurrence of complex regional pain syndrome was
analyzed.
Results: Three hundred and seventeen patients with 328 fractures were randomized to receive vitamin C, and ninety-
nine patients with ninety-nine fractures were randomized to receive a placebo. The prevalence of complex regional
pain syndrome was 2.4% (eight of 328) in the vitamin C group and 10.1% (ten of ninety-nine) in the placebo group
(p = 0.002); all of the affected patients were elderly women. Analysis of the different doses of vitamin C showed that
the prevalence of complex regional pain syndrome was 4.2% (four of ninety-six) in the 200-mg group (relative risk,
0.41; 95% confidence interval, 0.13 to 1.27), 1.8% (two of 114) in the 500-mg group (relative risk, 0.17; 95% confi-
dence interval, 0.04 to 0.77), and 1.7% (two of 118) in the 1500-mg group (relative risk, 0.17; 95% confidence inter-
val, 0.04 to 0.75). Early cast-related complaints predicted the development of complex regional pain syndrome
(relative risk, 5.35; 95% confidence interval, 2.13 to 13.42).
Conclusions: Vitamin C reduces the prevalence of complex regional pain syndrome after wrist fractures. A daily dose
of 500 mg for fifty days is recommended.
Level of Evidence: Therapeutic Level I. See Instructions to Authors for a complete description of levels of evidence.
omplex regional pain syndrome type I (formerly
known as reflex sympathetic dystrophy) is treated
symptomatically, and the clinical focus is on preven-
tion. In patients who have sustained major trauma, the capac-
ity of homeostasis can be overwhelmed, which can lead to
systemic inflammatory response syndrome and multiple-organ
distress syndrome1. Systemic inflammatory response syndrome
is an excessive inflammatory reaction to an event such as a
trauma, burn, or massive infection (as in the case of pancreati-
tis). These processes appear to be mediated by the same host-
derived inflammatory mediators2. In an earlier report, we sug-
gested a parallel between burn wounds and the development
of complex regional pain syndrome because of the inflam-
matory reaction and the involved microangiopathy3. Complex
regional pain syndrome and burn wounds may involve a cas-
cade of deterioration and exaggeration of a similar process.
C
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Tanaka et al. reported that, in the clinical setting, ascorbic
acid given in high doses during the first twenty-four hours of
burn resuscitation significantly reduces resuscitation fluid
volume requirements and wound edema4. The severity of
respiratory dysfunction was also reduced in these patients.
The increased vascular permeability in patients with burns is
a result of damage to the microvascular endothelial cells
caused by oxygen free radicals. Vitamin C reduces lipid per-
oxidation, scavenges hydroxyl radicals, protects the capillary
endothelium, and inhibits vascular permeability2,3. In a pre-
vious randomized trial, we reported that treatment with 500
mg of vitamin C, as compared with placebo, reduced the risk
of reflex sympathetic dystrophy in patients with nonopera-
tively treated wrist fractures3. Therefore, we performed a
dose-response study to replicate and further evaluate our
earlier findings. A steady state in human plasma at doses of
>200 mg of ascorbic acid (vitamin C) per day has been
reported5. We performed a multicenter dose-response study
of patients with all types of wrist fractures that were treated
operatively and nonoperatively; the analysis was performed
on the basis of the intention-to-treat principle.
Materials and Methods
Study Design
he trial was designed as a multicenter, randomized, con-
trolled study. Three hospitals in The Netherlands partici-
pated in the study. The appropriate medical ethics committees
of these three hospitals approved the study. An independent
physician was appointed (as required under Dutch legislation)
for the patients’ guidance in case they requested extra informa-
tion about clinical trials in general or this trial in particular.
Adult patients (defined as those who were eighteen years
of age or older) with a wrist fracture who were seen in the
emergency department of each hospital were asked by the
emergency department physician to participate in the study.
Patients with a fracture of both wrists were also included. All
wrist fractures were included, independent of treatment
choice. Nonoperative treatment consisted of the use of a plas-
ter cast, with the fracture being reduced under local anesthesia
if necessary. Operative treatment varied and was applied at the
surgeon’s discretion.
After informed consent had been obtained, the protocol
was initiated in the emergency department. Patients were
asked to start the trial medication from that moment, on the
day of the fracture. This medication was delivered in a box
containing 100 capsules, with two capsules to be taken once
daily for fifty days. Patients were allocated randomly to receive
either placebo or a dosage of 200, 500, or 1500 mg of vitamin
C daily.
The pharmacist in one of the participating hospitals,
who also made up the medication for the other hospitals, exe-
cuted the randomization in block form, with blocks of ten ac-
cording to a table of random numbers. All capsules had the
same appearance and taste. The trial was double-blind, with
the pharmacist being the only individual with access to the
code until the conclusion of the trial.
The end point of the study was defined as the presence
of complex regional pain syndrome at any time within one
year after the fracture. All participants and physicians were
unaware of the treatment allocation. Complex regional pain
syndrome was diagnosed by a physician in the treating depart-
ment and not by anyone involved in the conduct of the trial.
At the time of enrollment, specific study parameters
were recorded, including gender, age, the side of the fracture,
dominance, fracture type according to the AO/ASIF classifica-
tion system6, dislocation, reduction, the number of the box
containing the allocated treatment, drug intake, and the his-
tory with respect to previous wrist fractures or earlier episodes
of complex regional pain syndrome.
Patients were evaluated after one week, four or five
weeks (or when the cast was removed), six or seven weeks,
twelve weeks, and twenty-six weeks. After one year, patients
were interviewed by telephone or were sent an inquiry letter
with a postage-paid envelope for their reply. Fracture treat-
ment was not compromised by the protocol. If necessary, pa-
tients were seen more often and/or at other times. Attention
was paid to early complaints related to the cast, such as pain,
swelling, and numbness.
Complex regional pain syndrome type I was diagnosed
if four of the following five symptoms were present at the
wrist, including the area distal to the wrist (the hand and fin-
gers), and if they occurred (or increased) after activity: (1) un-
explained diffuse pain that was not normal in relation to the
stage of fracture treatment, (2) a difference in skin color rela-
tive to the other hand and wrist, (3) diffuse edema, (4) a dif-
ference in skin temperature relative to the other hand and
wrist, and (5) limited active range of motion of the wrist and
fingers that was unrelated to the stage of fracture treatment7.
If complex regional pain syndrome was diagnosed, the
end point of the study was reached and the protocol was ter-
minated to allow for the treatment of complex regional pain
syndrome.
Statistical Analysis
Statistical analysis was performed with SPSS version 11.0
(SPSS, Chicago, Illinois) and MedCalc version 9.2 (MedCalc
Software, Mariakerke, Belgium) software on a personal com-
puter. Sample and group sizes were estimated a priori with use
of results of our previous study, a planned power of 90%, and
a significance level (α) of 0.053.
The chi-square test, analysis of variance, and the Stu-
dent t test were used as applicable for univariate analysis. Mea-
sures of association, along with their confidence intervals,
were calculated with the Pearson chi-square test or the Fisher
exact test. The significant independent variables from the
univariate analysis were entered in a multivariate logistic re-
gression with the occurrence of complex regional pain syn-
drome as a dependent variable. The likelihood ratio backward
test was conducted to find the best-fit model by selecting the
variables one by one. The probability for entry was set at 0.05,
and the probability for removal was set at 0.10.
Kaplan-Meier curves with 95% confidence intervals
T
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were generated to show the time between the fracture and the
diagnosis of complex regional pain syndrome. The curves for
the placebo and vitamin C groups were compared with use of
a log-rank test.
Results
etween January 2001 and December 2004, we enrolled 416
patients with 427 fractures from a total population of
2137 patients with wrist fractures who presented to the three
emergency departments at the three hospitals. The follow-up
period ended in December 2005.
Ten patients had a bilateral fracture, and one had an ip-
silateral refracture. All fractures were assessed individually.
None of the randomized patients were excluded from the
study. No adverse events occurred.
Randomization involved 416 patients from the three
centers: 317 patients with 328 fractures received vitamin C,
and ninety-nine patients with ninety-nine fractures received a
placebo. The trial profile is shown in Figure 1. The 1721 pa-
tients who were excluded comprised 463 patients who refused
to take part for various reasons, 297 patients who wanted to be
sure that they received vitamin C, and 961 patients who had
not been invited to take part in the study.
The patients who were given vitamin C and those who
were given a placebo did not differ significantly in terms of de-
mographic characteristics (Table I). Analysis of the groups re-
ceiving the three different doses of vitamin C and the placebo
showed no significant differences with regard to gender, age,
the side of the fracture, dominance, fracture type, dislocation,
reduction, or treatment modality (Table I).
After one year, all patients were interviewed by tele-
phone, with the exception of eighteen patients who received
an inquiry letter and one patient who was visited at home. It
was not necessary to see any of the patients in the outpatient
B
Fig. 1
CONSORT E-Flowchart illustrating the trial profile. The CONSORT comprises a checklist and a flow diagram to help im-
prove the quality of reports of randomized controlled trials, offering a standard way for researchers to report trials.
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clinic again as there was no suspicion of a missed diagnosis of
complex regional pain syndrome. None of the patients were
lost to follow-up.
Twenty-five patients had been taking vitamin supple-
ments prior to the fracture. Of these, nine had been taking vi-
tamin B, two had been taking vitamin D, and thirteen had
been taking a multivitamin preparation. None of those
twenty-four patients had been consuming vitamin C in high
doses (>50 mg daily, which is the recommended daily intake),
and therefore none of them were excluded. The remaining pa-
tient had been taking 1000 mg of vitamin C daily. She was
asked to stop taking this supplement during the trial. In retro-
spect, she was randomized to 1500 mg of vitamin C daily.
The prevalence of complex regional pain syndrome was
2.4% (eight of 328) in the vitamin C group and 10.1% (ten of
ninety-nine) in the placebo group (p = 0.002) (Table I). All of
the affected patients were elderly women. For the entire co-
hort, the prevalence of complex regional pain syndrome was
4.2% (eighteen of 427).
Analysis of the different doses of vitamin C showed that
the prevalence of complex regional pain syndrome in the 200-
mg group (4.2%; four of ninety-six) was lower than that among
those in the placebo group (10.1%; ten of ninety-nine) (Table
I), but this difference was not significant (relative risk, 0.41;
95% confidence interval, 0.13 to 1.27) (Table II). Significant dif-
ferences were seen in the 500 (p = 0.007) and 1500-mg (p =
0.005) groups, in which the relative risks of complex regional
pain syndrome were 0.17 (95% confidence interval, 0.04 to
0.77) and 0.17 (95% confidence interval, 0.04 to 0.75), respec-
tively. Overall, there was a significant difference between the vi-
TABLE I Demographic Data 
Vitamin C 
200 mg 
(N = 96)
Vitamin C 
500 mg 
(N = 114)
Vitamin C 
1500 mg 
(N = 118)
Placebo 
(N = 99)
Vitamin C 
200 mg, 500 mg, 
1500 mg 
(N = 328) P Value† P Value‡
Gender (no. of fractures) 0.796 0.431
Female 80 (83%) 93 (82%) 100 (85%) 79 (80%) 273 (83%)
Male 16 (17%) 21 (18%) 18 (15%) 20 (20%) 55 (17%)
Age* (yr) 62.8 ± 17.2 62.8 ± 15.0 62.4 ± 18.3 61.4 ± 18 62.7 ± 16.8 0.930 0.522
Side of the fracture 
(no. of fractures)
0.905 0.996
Right 42 (44%) 55 (48%) 52 (44%) 45 (45%) 149 (45%)
Left 54 (56%) 59 (52%) 66 (56%) 54 (55%) 179 (55%)
Dominance§ (no. of fractures) 0.946 0.687
Yes 46 (48%) 51 (45%) 54 (46%) 48 (48%) 151 (46%)
No 50 (52%) 63 (55%) 63 (54%) 51 (52%) 176 (54%)
Fracture type (no. of fractures)  0.571 0.447
23-A 57 (59%) 65 (57%) 57 (48%) 52 (53%) 179 (55%)
23-B 20 (21%) 23 (20%) 29 (25%) 18 (18%) 72 (22%)
23-C 19 (20%) 26 (23%) 32 (27%) 29 (29%) 77 (23%)
Dislocation (no. of fractures) 0.524 0.970
Yes 58 (60%) 79 (69%) 81 (69%) 66 (67%) 218 (66%)
No 38 (40%) 35 (31%) 37 (31%) 33 (33%) 110 (34%)
Reduction (no. of fractures) 0.150 0.861
Yes 50 (52%) 76 (67%) 76 (64%) 60 (61%) 202 (62%)
No 46 (48%) 38 (33%) 42 (36%) 39 (39%) 126 (38%)
Treatment (no. of fractures) 0.891 0.963
Conservative 86 (90%) 99 (87%) 106 (90%) 88 (89%) 291 (89%)
Operative 10 (10%) 15 (13%) 12 (10%) 11 (11%) 37 (11%)
Complex regional pain 
syndrome (no. of fractures)
0.007 0.002
Yes 4 (4%) 2 (2%) 2 (2%) 10 (10%) 8 (2.4%)
No 92 (96%) 112 (98%) 116 (98%) 89 (90%) 320 (97.6%)
*The values are given as the mean and the standard deviation. †Placebo group compared with the three different vitamin-C groups. ‡Placebo
group compared with overall vitamin-C group. §This information was missing for one fracture.
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tamin C group and the placebo group (relative risk, 0.24; 95%
confidence interval, 0.10 to 0.60) (p = 0.002) (Table II).
In the present study, all patients with complex regional
pain syndrome were female; for male patients, the relative risk
that complex regional pain syndrome would not develop was
0.95 (95% confidence interval, 0.93 to 0.97). Complex re-
gional pain syndrome occurred significantly more frequently
in older patients (Table II).
One patient had a refracture and was randomized twice
over an interval of four months, the first time to 500 mg and
the second time to 1500 mg of vitamin C. Fracture treatment
was nonoperative on both occasions, and complex regional
pain syndrome did not develop.
One seventy-four-year-old patient in the 1500-mg vita-
min C group who had a fracture of both wrists had develop-
ment of complex regional pain syndrome on the right side,
where she had a simple AO 23-A2-type fracture that had been
inadequately reduced. On the left side, where the patient had
an adequately reduced AO 23-A3-type fracture, there were no
signs of complex regional pain syndrome.
Complex regional pain syndrome was not associated
with the side of the fracture, dominance, the type of fracture,
the need to undergo reduction, or the type of treatment (op-
erative or nonoperative) (Table II).
Early complaints related to the plaster cast were predictive
of the occurrence of complex regional pain syndrome (relative
TABLE II Relative Risk of Complex Regional Pain Syndrome
Characteristic
Complex Regional 
Pain Syndrome
(N = 18)
No Complex 
Regional Pain 
Syndrome (N = 409)
Relative Risk (95% 
Confidence Interval) P Value
Gender (no. of fractures) 0.95 (0.93 to 0.97)*
Female 18 (100%) 334 (82%)
Male 0 (0%) 75 (18%)
Age† (yr) 67.6 ± 7.7 62.1 ± 17.4 0.011
Side of the fracture (no. of fractures) 0.96 (0.39 to 2.39)
Right 8 (44%) 186 (45%)
Left 10 (56%) 223 (55%)
Dominance‡ (no. of fractures) 1.14 (0.46 to 2.82)
Yes 9 (50%) 190 (46%)
No 9 (50%) 218 (53%)
Fracture type (no. of fractures) 0.821
23-A 11 (61%) 220 (54%)
23-B 3 (17%) 87 (21%)
23-C 4 (22%) 102 (25%)
Dislocation (no. of fractures) 1.31 (0.48 to 3.6)
Yes 13 (72%) 271 (66%)
No  5 (28%) 138 (34%)
Reduction (no. of fractures) 0.99 (0.39 to 2.5)
Yes 11 (61%) 251 (61%)
No 7 (39%) 158 (39%)
Cast-related complaints (no. of fractures) 11 (61%) 86 (22%)§ 5.35 (2.13 to 13.42)
Prevention (no. of fractures)
Placebo 10 (56%) 89 (22%)
Vitamin C 200 mg 4 (22%) 92 (22%) 0.41 (0.13 to 1.27)
Vitamin C 500 mg 2 (11%) 112 (27%) 0.17 (0.04 to 0.77)
Vitamin C 1500 mg 2 (11%) 116 (28%) 0.17 (0.04 to 0.75)
Vitamin C overall 8 (44%) 320 (78%) 0.24 (0.10 to 0.60)
Treatment (no. of fractures) 0.46 (0.06 to 3.41)
Conservative 17 (94%) 362 (89%)
Operative 1 (6%) 47 (11%)
*Relative risk calculated for no complex regional pain syndrome. †The values are given as the mean and the standard deviation. ‡This infor-
mation was missing for one fracture. §Data on cast-related complaints were missing for fifteen fractures (with no complex regional pain syn-
drome), so this percentage is based on 394 fractures.
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risk, 5.35; 95% confidence interval, 2.13 to 13.42). Overall,
complex regional pain syndrome was diagnosed at an average of
seventy-six days (range, thirty to 166 days) after the fracture
(Fig. 2). The diagnosis of complex regional pain syndrome was
made earlier for the patients in the vitamin C group than for
those in the placebo group (sixty-eight compared with eighty-
three days), but this difference was not significant.
The logistic regression analysis of the predictive factors
yielded significant odds ratios for cast-related complaints and
vitamin C doses of 500 and 1500 mg daily (Table III).
Discussion
he present study confirms that vitamin C can have an in-
hibiting effect on the occurrence of complex regional
pain syndrome after wrist fractures. Some limitations of the
study should be mentioned.
The number of patients enrolled in the study was low in
relation to the number of eligible patients who presented with
wrist fractures, but after randomization no patient was lost to
follow-up. It is difficult in an emergency department setting to
motivate staff and patients to participate in any study. The
possible lack of interest explains the high number of uninvited
patients (961). Furthermore, during the informed-consent
process, patients were informed about our previous study3,
which showed a positive effect of vitamin C. Therefore, 297
patients wanted to be sure that they received vitamin C and
decided not to participate in the study.
The confidence intervals for all reported values were
wide. Our power analysis was based on our previous study3,
but the prevalence of complex regional pain syndrome in the
present study was lower than expected.
In The Netherlands, the intake of vitamin supplements
is slowly increasing but is still low. Only twenty-five patients
had already been taking vitamin supplements before the oc-
currence of the wrist fracture. None of them had been taking
high-dose vitamin C (>50 mg daily) (except for the patient
T
Fig. 2
Kaplan-Meier survivorship curves (with 95% confidence intervals) for the vitamin C and placebo groups, with the occurrence 
of complex regional pain syndrome (CRPS) as the end point. 0 = placebo, 1 = vitamin C, and df = degrees of freedom.
TABLE III Results of Logistic Regression Analysis
Odds Ratio (95% Confidence Interval) P Value
Cast-related complaints 5.73 (2.11 to 15.57) 0.001
Vitamin C overall 0.22 (0.08 to 0.58) 0.020
Vitamin C 200 mg 0.38 (0.11 to 1.30) 0.122
Vitamin C 500 mg 0.14 (0.03 to 0.68) 0.014
Vitamin C 1500 mg 0.16 (0.03 to 0.77) 0.022
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mentioned earlier, who had been asked to stop doing so), and
therefore none of those patients were excluded. Because of the
low numbers of patients who were known to have been taking
supplements before the fracture and the high doses that were
used in the study, this source of bias was limited. It is known
that vitamin C rapidly reaches a steady state in human plasma
at doses of >200 mg per day5. With a normal dietary intake of
50 to 60 mg of vitamin C per day added to our trial doses, we
did not believe that there was a need to measure plasma levels
of vitamin C. Compliance with taking the vitamins as recom-
mended was not confirmed; however, all patients stated that
they had consumed all fifty doses.
The overall prevalence of complex regional pain syn-
drome in the present study was 4.2%, and the prevalence for
the placebo group was 10.1%. This rate in the placebo group
is lower than those in our previous study3 (22%) and in the
studies reported by Atkins et al.8,9 (25% and 37%, respec-
tively). A possible explanation for the lower prevalence in
the present study might be found in the more precise criteria
(as described by Veldman et al.7) that we used for the diag-
nosis of complex regional pain syndrome. In the present
study the diagnosis was made if four of five symptoms were
present, whereas in our previous study the diagnosis was
made if four of six symptoms were present. Clinicians in The
Netherlands are more acquainted with the criteria of Veld-
man et al.7 than they are with other criteria such as those
from the International Association for the Study of Pain (the
so-called IASP criteria) or the modified research criteria
proposed by Bruehl and others10,11. Another reason for the
lower prevalence might be the fact that surgically treated
wrist fractures were included in the present study. The num-
ber needed to treat (NNT) was 12 for the 500-mg dose of vi-
tamin C in this study.
We found that complaints related to the use of the plas-
ter cast were strongly predictive of the development of com-
plex regional pain syndrome. This finding has been described
in previous studies3,12 and should alert physicians who treat
fractures with a plaster cast. In the present study, all patients
with complex regional pain syndrome were female, and this
was significant in univariate analysis. From this observation
that complex regional pain syndrome occurs more often in
elderly women, the suggestion has been made that estrogen
status could be a confounding factor3.
The mean time-interval between the wrist fracture and
the diagnosis of complex regional pain syndrome was seventy-
six days for all cases. The mean interval was sixty-eight days
for patients in the vitamin C group and eighty-three days for
patients in the placebo group. The length of this time-interval
is consistent with the results reported by Geertzen et al., who
reported a mean interval of 2.3 months for the development
of upper limb complex regional pain syndrome resulting from
various causes13.
The pharmacodynamic behavior of vitamin C in the
treatment of fracture or the prevention of complex re-
gional pain syndrome is not fully understood. Nevertheless,
previous studies have shown a positive effect of vitamin C in
different healing processes. Yilmaz et al., in a study of experi-
mental fractures in rats, suggested that vitamin C enhanced
fracture-healing in comparison with that in a control
group14, and Sarisozen et al. confirmed that vitamin C accel-
erated fracture-healing in rats15. We did not study the time
needed for fracture-healing.
Ischemia-reperfusion injury is caused by endothelial
and subendothelial damage by neutrophil-derived oxidants5.
Kearns et al. noted that pretreatment with oral vitamin C
protected against this injury in rats, possibly by diminishing
neutrophil respiratory burst activity5. In a later study, they
provided experimental evidence of a potential role for antioxi-
dants, such as vitamin C, in the reduction of injury to skeletal
muscle caused by compartment syndrome16. With the knowl-
edge that the production of oxidants in neutrophils is reduced
by the administration of vitamin C and that vitamin C can
protect the endothelium from direct injury by oxidants, one
can postulate that it can prevent microvascular dysfunction
and the microangiopathy of an inflammatory reaction as is
seen in complex regional pain syndrome2,17-20.
The strength of our conclusion is limited by two issues.
First, our two vitamin C studies yielded relative risks with
wide confidence intervals, which must be interpreted as a lack
of precision, limiting the validity of our conclusion. Second,
with vitamin C, we prevented a group of symptoms defined by
us as complex regional pain syndrome. Due to the lack of pre-
cision with this diagnosis, we cannot be sure that we actually
prevented complex regional pain syndrome.
In conclusion, we recommend the administration of 500
mg of vitamin C daily for fifty days after a wrist fracture be-
cause we believe that such treatment may prevent complex re-
gional pain syndrome. Whether vitamin C can also be used as
a treatment for complex regional pain syndrome should be the
subject of further study. 
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